US FDA approves Amgen's colorectal cancer therapy
1. FDA approved Amgen's therapy for colorectal cancer with specific gene mutation. 2. This approval could enhance Amgen's revenue from oncology treatments.
FAQ
Why Bullish?
The approval opens a new market for AMGN, similar to previous oncology breakthroughs.
How important is it?
The article discusses significant approval that may drive future revenue for AMGN.
Why Long Term?
Sustained growth in cancer treatment demand could benefit AMGN over time, like earlier therapies.